Patent · US Active

NEAT1 as a prognostic marker and therapeutic target for prostate cancer

US10294476B2 · kind B2 · utility

0Cited by

0References

24Claims

0Family size

Assignee

Cornell University · IT

Inventors

Dimple Chakravarty · New York, US
Mark A. Rubin · New York, US

Key dates

Filing date	Apr 17, 2015
Grant date	May 21, 2019
Priority date	—
Expiry date	Apr 17, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to diagnosis and prognosis of prostate cancer, as well as therapeutic treatment of prostate cancer. More specifically, the invention provides diagnostic and prognostic methods based on detecting nuclear enriched abundant transcript 1 (NEAT1) levels in a sample. Further provided are methods for treating prostate cancer based on targeting NEAT1 via interfering RNA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.